Sarilumab clinical trials
Also written REGN88, Kevzara® and SAR153191.
How each study uses sarilumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sarilumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 May 2017 · KEVZARA · BLA 761037 (FDA, Drugs@FDA)
- European Union
- 23 Jun 2017 · Kevzara · EMEA/H/C/004254 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2020 (10)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2010 | 7 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 10 |
| 2021 | 2 |
| 2023 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 19
Sanofi (22) · Regeneron Pharmaceuticals (5) · M.D. Anderson Cancer Center (1) · Assistance Publique - Hôpitaux de Paris (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Stanford University (1) · Maimónides Biomedical Research Institute of Córdoba (1) · Maria del Rosario Garcia de Vicuña Pinedo (1)
Often tested with
Tested in the same studies.
Tocilizumab (3) · Cemiplimab (2) · Hydroxychloroquine (2) · Baricitinib (2) · Adalimumab (2) · Lopinavir-ritonavir drug combination (1) · Lopinavir (1) · Ritonavir (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test sarilumab.
- Nov 2026A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)Phase 1/2 · University of Southern California
Studies
Open first, then newest update. How each study uses sarilumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 46
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Sarilumab
- Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse EventsNot yet recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07836101Written as Sarilumab
- Sarilumab Efficacy and Safety in Adults With Early Polymyalgia RheumaticaRecruitingPhase 3SanofiNCT07286214Written as Sarilumab
- A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)RecruitingPhase 2SanofiNCT02991469Written as Sarilumab SAR153191 (REGN88)
- Phase 1b/2 Study of IV Sarilumab in Adult With RARecruitingPhase 1/2SanofiNCT07704580Written as Sarilumab, SAR153191 SC
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingPhase 3University of NebraskaNCT03414502Written as Sarilumab
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Sarilumab + Cemiplimab + Paclitaxel
- A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)RecruitingPhase 1/2University of Southern CaliforniaNCT04333706Written as Sarilumab 150mg or 200 mg plus Capecitabine
- A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.Active, not recruitingPhase 1M.D. Anderson Cancer CenterNCT05704634Written as Kevzara (Sarilumab)
- Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19WithdrawnPhase 2BayCare Health SystemNCT07196306Written as Sarilumab 200 MG/1.14 ML Subcutaneous Solution
- Sarilumab COVID-19CompletedPhase 3SanofiNCT04327388Written as Sarilumab SAR153191
- Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARICompletedPhase 2/3Assistance Publique - Hôpitaux de ParisNCT04324073Written as Sarilumab
- Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic MastocytosisCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03770273Written as sarilumab
- An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)CompletedPhase 2SanofiNCT02776735Written as Sarilumab
- Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male SubjectsCompletedPhase 1SanofiNCT06159452Written as SAR153191-P3 drug product
- Sarilumab in Patients With Glucocorticoid-Dependent SarcoidosisCompletedPhase 2Stanford UniversityNCT04008069Written as Sarilumab
- Study on the Use of Sarilumab in Patients With COVID-19 InfectionWithdrawnEarly Phase 1ASST Fatebenefratelli SaccoNCT04386239Written as Sarilumab Prefilled Syringe
- Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid ArthritisTerminatedPhase 1/2University of Southern DenmarkNCT04842981Written as Sarilumab
- Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia RheumaticaTerminatedPhase 3SanofiNCT03600818Written as Sarilumab SAR153191 (REGN88)
- Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid ArthritisCompletedPhase 4SanofiNCT03449758Written as SARILUMAB
See all 46 studies that test sarilumab →
Given beside what is tested · 13 — sarilumab is usual care or a partner of the new treatment
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingPhase 2Regeneron PharmaceuticalsNCT06787612Written as Sarilumab
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaRecruitingPhase 2NYU Langone HealthNCT05428007Written as Sarilumab
- A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Regeneron PharmaceuticalsNCT07154290Written as Sarilumab
- REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult ParticipantsNot yet recruitingPhase 1/2Regeneron PharmaceuticalsNCT07850921Written as Sarilumab Prophylaxis (Contingency)
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRecruitingPhase 1/2Regeneron PharmaceuticalsNCT03564340Written as Sarilumab
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamatamabRecruitingPhase 1/2Regeneron PharmaceuticalsNCT04590326Written as Sarilumab
- IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHDNot yet recruitingPhase 1Stanford UniversityNCT07484113Written as Sarilumab
- Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingPhase 2/3Wei-Che KoNCT05535738Written as Sarilumab
- Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIROSuspendedPhase 2/3Assistance Publique - Hôpitaux de ParisNCT04341870Written as Sarilumab
- A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)CompletedPhase 3SanofiNCT02293902Written as Sarilumab SAR153191 (REGN88)
- To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid ArthritisCompletedPhase 3SanofiNCT02057250Written as Sarilumab
- Sarilumab Effect on the Pharmacokinetics of SimvastatinCompletedPhase 1SanofiNCT02017639Written as sarilumab SAR153191 (REGN88)
- Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid ArthritisCompletedPhase 1SanofiNCT01850680Written as sarilumab SAR153191 (REGN88)
As the comparator · 1 — what is tested is compared with sarilumab
Codes
What other systems call sarilumab · ClinicalTrials.gg INT000092
- MeSH (NLM) C000592401sarilumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) NU90V55F8ISARILUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1923319Confirmed FDA, Wikidata
- Wikidata Q7424081sarilumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152302SarilumabOne source FDA
- DrugBank DB11767One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592401 | sarilumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | NU90V55F8I | SARILUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1923319 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7424081 | sarilumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152302 | Sarilumab | One source FDA |
| DrugBank | DB11767 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.